title: The phosphatidylinositol (PI)-5-phosphate 4-kinase type II enzyme controls insulin signaling by regulating PI-3,4,5-trisphosphate degradation.
abstract: Phosphatidylinositol-5-phosphate (PI-5-P) is a newly identified phosphoinositide with characteristics of a signaling lipid but no known cellular function. PI-5-P levels are controlled by the type II PI-5-P 4-kinases (PIP4K IIs), a family of kinases that converts PI-5-P into phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2). The PI-5-P pathway is an alternative route for PI-4,5-P2 synthesis as the bulk of this lipid is generated by the canonical pathway in which phosphatidylinositol-4-phosphate (PI-4-P) is the intermediate. Here we examined the effect of activation of the PI-5-P pathway on phosphoinositide 3-kinase (PI3K) signaling by expressing PIP4K II beta in cells that lack this enzyme. Although PIP4K II generates PI-4,5-P2, a substrate for PI3K, expression of this enzyme reduced rather than increased phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) levels in cells stimulated with insulin or cells expressing activated PI3K. This reduction in PI-3,4,5-P3 levels resulted in decreased activation of the downstream protein kinase, Akt/PKB. Consistent with these results, expression of IpgD, a bacterial phosphatase that converts PI-4,5-P2 to PI-5-P, resulted in Akt activation, and this effect was partially reversed by PIP4K II beta. PIP4K II beta expression did not impair insulin-dependent association of PI3K with insulin receptor substrate 1 (IRS1) but abbreviated Akt activation, indicating that PIP4K II regulates PI-3,4,5-P3 degradation rather than synthesis. These data support a model in which the PI-5-P pathway controls insulin signaling that leads to Akt activation by regulating a PI-3,4,5-P3 phosphatase.
authors.affiliation: Boston Biomedical Research Institute, 64 Grove Street, Watertown, MA 02472, USA.
authors.forename: Valerie
authors.initials: V
authors.lastname: Carricaburu
authors.forename: Katja A
authors.initials: KA
authors.lastname: Lamia
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Lo
authors.forename: Laetitia
authors.initials: L
authors.lastname: Favereaux
authors.forename: Bernard
authors.initials: B
authors.lastname: Payrastre
authors.forename: Lewis C
authors.initials: LC
authors.lastname: Cantley
authors.forename: Lucia E
authors.initials: LE
authors.lastname: Rameh
mesh_terms: D000818:Animals; D001426:Bacterial Proteins / Q000378:metabolism; D016466:CHO Cells; D019556:COS Cells; D006224:Cricetinae; D015536:Down-Regulation; D006801:Humans; D007328:Insulin / Q000378:metabolism*; D008954:Models, Biological; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D018129:Phosphatidylinositol Phosphates / Q000378:metabolism*; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D010766:Phosphorylation; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000145:classification / Q000235:genetics / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt; D011972:Receptor, Insulin / Q000235:genetics / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012763:Shigella flexneri / Q000201:enzymology / Q000235:genetics; D015398:Signal Transduction
chemical_list: D001426:Bacterial Proteins; D007328:Insulin; D019869:Phosphatidylinositol 3-Kinases; D018129:Phosphatidylinositol Phosphates; D010744:Phosphoric Monoester Hydrolases; D017853:Phosphotransferases (Alcohol Group Acceptor); D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D011972:Receptor, Insulin; D011994:Recombinant Proteins; C060974:phosphatidylinositol 3,4,5-triphosphate; C113567:phosphatidylinositol 5-phosphate; C020077:1-phosphatidylinositol-4-phosphate 5-kinase; C494918:AKT1 protein, human; C425774:IpgD protein, Shigella flexneri